All filters
Abstracts
Evaluation of HIV-1 tropism in multidrug-resistant cART failing patients
Y. Bouba Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
DTG+3TC vs DTG+TDF/FTC (GEMINI1&2): Confirmed Virologic Withdrawals Through Week 96
J. van Wyk Reviews in Antiviral Therapy & Infectious Diseases 7, 2020  
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Emergence of Resistance in HIV-1 Integrase following Dolutegravir Treatment in Participants Aged 4 Weeks to <18 Years: Results from the IMPAACT P1093 Study
C. Vavro Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Assessment of Genotypic Patterns Associated with HIV-1 Sensitivity to Ibalizumab
H. Jullien Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations
F. Giammarino Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Detection in HIV proviral DNA of drug resistance mutations in patients with low permanent viral loads
P. Ferrer  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
HIV-DNA decay in ART-naïve patients starting a DTG-based dual vs triple therapy
F. Lombardi Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Role of analytical treatment interruption on HIV peripheral reservoir diversification
C. Alteri  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Case report: poor adherence to dolutegravir is associated with selection of resistance mutations T66I, G118R, E138A and L74I
M. Pauskar Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Integrase Resistance development after long-term suppressive treatment with Abacavir, Lamivudine and Dolutegravir
M. Obermeier  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Difficulty in reaching virological suppression in a long-term treated HIV-1 patient: rather the role of the reservoir than drug resistance?
E. Alidjinou Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Assessment of quality of life among patients with hepatitis C in Georgia
T. Abzianidze Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
HIV Seronegativity After Rapid ART: A Case Demonstrating Future Challenges in HIV Confirmation Testing in the Era of iART
K. Yan Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Multicentric Castleman Disease HHV-8 related in a HIV patient
A. Gjataj Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Variability in HIV Proviral DNA Genotyping Results from a Single Blood Draw
K. White  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Virological efficacy and resistance evaluation in people living with HIV starting an STR regimen
G. Stella Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Resistant minority variants observed in failing patients at week 48 in ANRS 170 QUATUOR trial (a 4/7 days maintenance strategy vs a 7/7 days regimen in patients with controlled viral load)
S. Lambert-Niclot  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Molecular characterization in HCV late relapser patients treated with direct-acting antiviral (DAA) drugs
M. Rueca Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Clinical and virological characteristics and retreatment of patients with chronic hepatitis C virus infection and failure to sofosbuvir, velapatasvir, and voxilaprevir in real-world
F. García Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Pharmaco-virological algorithm to target risk of resistance among a population of HIV-infected female sex workers in Togo
V. Ferré Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Characterization of the NS5A gene of HCV genotype 4 isolates from HIV-1 co-infected patients in a third-level hospital in Mexico
R. Rodriguez-Díaz  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Impact of Sexually Transmitted Infections on seminal HIV levels among undetectable patients
R. Scutari Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020